245 related articles for article (PubMed ID: 21426474)
1. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity.
Kamat AM; Karam JA; Grossman HB; Kader AK; Munsell M; Dinney CP
BJU Int; 2011 Oct; 108(7):1119-23. PubMed ID: 21426474
[TBL] [Abstract][Full Text] [Related]
2. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
3. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
4. Non-muscle-invasive bladder cancer surveillance for which cystoscopy is partly replaced by microsatellite analysis of urine: a cost-effective alternative?
de Bekker-Grob EW; van der Aa MN; Zwarthoff EC; Eijkemans MJ; van Rhijn BW; van der Kwast TH; Steyerberg EW
BJU Int; 2009 Jul; 104(1):41-7. PubMed ID: 19500328
[TBL] [Abstract][Full Text] [Related]
5. The role of fluorescence in situ hybridization assay for surveillance of non-muscle invasive bladder cancer.
Karnwal A; Venegas R; Shuch B; Bassett J; Rajfer J; Reznichek R
Can J Urol; 2010 Apr; 17(2):5077-81. PubMed ID: 20398445
[TBL] [Abstract][Full Text] [Related]
6. Suspicious urine cytology (class III) in patients with bladder cancer: should it be considered as negative or positive?
Raitanen MP; Aine RA; Kaasinen ES; Liukkonen TJ; Kylmälä TM; Huhtala H; Tammela TL;
Scand J Urol Nephrol; 2002; 36(3):213-7. PubMed ID: 12201938
[TBL] [Abstract][Full Text] [Related]
7. Surveillance of patients with bladder carcinoma using fluorescent in-situ hybridization on bladder washings.
Bergman J; Reznichek RC; Rajfer J
BJU Int; 2008 Jan; 101(1):26-9. PubMed ID: 17850364
[TBL] [Abstract][Full Text] [Related]
8. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
9. Urinary NMP22 BladderChek test in the diagnosis of superficial bladder cancer.
Moonen PM; Kiemeney LA; Witjes JA
Eur Urol; 2005 Dec; 48(6):951-6; discussion 956. PubMed ID: 16257108
[TBL] [Abstract][Full Text] [Related]
10. The UroVysion fluorescence in situ hybridization assay is an effective tool for monitoring recurrence of bladder cancer.
Varella-Garcia M; Akduman B; Sunpaweravong P; Di Maria MV; Crawford ED
Urol Oncol; 2004; 22(1):16-9. PubMed ID: 14969798
[TBL] [Abstract][Full Text] [Related]
11. Role of fluorescence in situ hybridization in bladder cancer surveillance of patients with negative cytology.
Youssef RF; Schlomer BJ; Ho R; Sagalowsky AI; Ashfaq R; Lotan Y
Urol Oncol; 2012; 30(3):273-7. PubMed ID: 20451422
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder.
Lotan Y; Bensalah K; Ruddell T; Shariat SF; Sagalowsky AI; Ashfaq R
J Urol; 2008 Jun; 179(6):2164-9. PubMed ID: 18423745
[TBL] [Abstract][Full Text] [Related]
13. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
14. Urinary CYFRA 21.1 is not a useful marker for the detection of recurrences in the follow-up of superficial bladder cancer.
Fernandez-Gomez J; Rodríguez-Martínez JJ; Barmadah SE; García Rodríguez J; Allende DM; Jalon A; Gonzalez R; Alvarez-Múgica M
Eur Urol; 2007 May; 51(5):1267-74. PubMed ID: 17207912
[TBL] [Abstract][Full Text] [Related]
15. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
16. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
18. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
19. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings.
Yoder BJ; Skacel M; Hedgepeth R; Babineau D; Ulchaker JC; Liou LS; Brainard JA; Biscotti CV; Jones JS; Tubbs RR
Am J Clin Pathol; 2007 Feb; 127(2):295-301. PubMed ID: 17210520
[TBL] [Abstract][Full Text] [Related]
20. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
